Wills Innovation Spółka z Ograniczoną Odpowiedzialnością (KRS 0001096748, NIP 8992989359) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. Wills Innovation operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since March 26, 2024. Wills Innovation's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Wills Innovation
Identity
- Name
- Wills Innovation Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- March 26, 2024
- Registry status as of
- July 13, 2026
- Latest entry
- July 13, 2026
- Founding act
- 20.03.2024
Articles of association history (2)
- March 20, 2024: 20.03.2024
- April 10, 2025: 10.04.2025 R. REP. A NR 14527/2025 NOTARIUSZ WOJCIECH KAMIŃSKI Z KANCELARII NOTARIALNEJ WE WROCŁAWIU PRZY UL. RUSKIEJ 3/4, ZMIENIONO § 4 UMOWY SPÓŁKI; 03.09.2025 R. REP. A NR 33152/2025 NOTARIUSZ WOJCIECH KAMIŃSKI Z KANCELARII NOTARIALNEJ WE WROCŁAWIU PRZY UL. RUSKIEJ 3/4, ZMIENIONO § 5 I DODANO § 6(1) UMOWY SPÓŁKI
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. ŻYCZLIWA, 33, 2, 50-030, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- W.PASTUCHA@WILLS.PL
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-42734-37359-VGUCJ-24
Risk and payment profile - Wills Innovation
Credibility rating
54.1 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
14
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/2 yrs
Board changes
0
0/2 yrs
PKD changes
1
1/2 yrs
Name changes
0
0/2 yrs
Data from 2 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Wills Innovation
Founded
March 26, 2024
2 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
5.5 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
1 year
2024
Registry entries
8
latest: July 13, 2026
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
5.0 K PLN
2024
Equity
5.0 K PLN
2024
Valuation
4.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Wills Innovation.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
